Artelo Biosciences Shares Rise 8% on Acceptance Into U.K Oncology Program
2021年3月19日 - 11:49PM
Dow Jones News
By Chris Wack
Artelo Biosciences Inc. shares rose 8% to $2.11 after the
company said it has been accepted into the first round of the
Alderley Park Oncology Development Program, a U.K. national program
designed to offer advice, guidance, and financial support to
develop and progress innovative oncology projects.
The biopharmaceutical company said the program is funded by
Innovate UK and Cancer Research UK and supported by major
oncology-focused pharmaceutical companies including AstraZeneca,
Johnson & Johnson, GlaxoSmithKline and Roche.
Artelo's application is focused on developing a pathway to a
validated FABP5 biomarker.
The company said this acceptance could bring additional funding
to its overall FABP5 inhibitor program, which has separately
received nearly $8 million in support from the U.S. government and
can allow its scientists to collaborate with leading UK research
institutes and leading oncology pharmaceutical companies to develop
a personalized medicine strategy for ART26.12.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 19, 2021 10:34 ET (14:34 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024
